Aktie A2PBHX TCR2 THERAPEUTICS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen TCR2 Therapeutics Inc.

Aktien

A2PBHX

US87808K1060

TCRR

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from NASDAQ Composite Index
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P Global BMI Index
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P TMI Index
Adaptimmune Therapeutics plc completed the acquisition of TCR2 Therapeutics Inc. from a group of shareholders.
TCR2 THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
TCR2 Therapeutics : Merger Agreement - Form 8-K
TCR-2 THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
TCR2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
TCR2 THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
TCR-2 THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
North American Morning Briefing : Stock Futures -2-
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PBHX Aktie
  4. Nachrichten TCR2 Therapeutics Inc.
  5. Andere Sprachen